Supernus Pharmaceuticals, Inc.

Quick facts

Marketed products

• MYOBLOC · Neurology
  MYOBLOC is a botulinum toxin type B that blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins.
• SPN-538 · Other
• SPN-812 · Other
• SPN-812 (600mg, QD) · Psychiatry / Neurology
  SPN-812 is a selective norepinephrine reuptake inhibitor that increases norepinephrine availability in the central nervous system to improve attention and executive function.
• ZULRESSO® · Neuroscience

Phase 3 pipeline

• Oxcarbazepine XR · Neurology
  Oxcarbazepine XR is an extended-release anticonvulsant that blocks voltage-gated sodium channels to reduce neuronal excitability and prevent seizures.
• SAGE-547 · Neurology
  SAGE-547 is an intravenous formulation of an antisense oligonucleotide that targets the GABA_A receptor alpha 1 subunit.
• SPN-810 (18 mg) · Psychiatry/Neurology
  SPN-810 is a selective serotonin 5-HT1A receptor agonist that modulates serotonergic neurotransmission to reduce impulsivity and improve behavioral control.
• SPN-810 (36 mg) · Psychiatry
  SPN-810 is a proprietary formulation of a divalproex sodium extended-release product designed to treat disruptive mood dysregulation disorder (DMDD).

Phase 2 pipeline

• Phase 2; High Dose MYOBLOC
• Phase 2; Low Dose MYOBLOC
• Phase 3; MYOBLOC
• SPN-817

Phase 1 pipeline

• BIS-001 ER
• BIS-001, Treatment A
• BIS-001ER
• IR Viloxazine
• SAGE-904
• SPN-804O
• SPN-810M
• SPN-817, Treatment B
• SPN-817, Treatment C
• Topiramate ER
• Topiramate IR
• TPM XR

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Supernus Pharmaceuticals, Inc. portfolio CI brief
• Supernus Pharmaceuticals, Inc. pipeline updates RSS